HTB South


Pipeline ART: tenofovir alafenamide (TAF)

Pipeline ART: maturation inhibitors and an attachment inhibitor

PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP

Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep

HIV persists in lung macrophages of people on suppressive ART

Risk of CVD or type-2 diabetes according to change in BMI after starting ART

Pill A, Pill B: simplified second-line treatment for low-income countries

Update on paediatric antiretrovirals

Is d4T a viable option for children in low-income countries?

Short-term safety of atazanavir/ritonavir-based second line treatment in Zambia

Uptake of ART is influenced by distance to the health facility in rural Zambia

ARV pipeline: doravirine, GSK-744 and BMS-068

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

Pharmacokinetic targets for efavirenz might be too high

Women, HIV research and antiretrovirals

Outcomes in infants exposed to lopinavir/ritonavir in utero

Two percent rate of efavirenz discontinuation in an ART programme in Malawi

Raltegravir safe and effective in pregnancy in small French study

Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

Good safety profile with long-acting integrase inhibitor GSK744

TAF comparable to TDF in once-daily pill for ART-naive: 48-week results

Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial

High prices for antiretrovirals in middle-income countries outside Africa

Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

PrEP gives little extra benefit in attempted conception if male partner is on ART

Cobicistat approved as pharmacokinetic (PK) booster for atazanavir and darunavir in EU prior to the US

NHS England approves four-in-one Stribild (Quad) for limited use

Dolutegravir approved in the US

ViiV goes for gold: US premium pricing may make dolutegravir redundant in the UK

From sky high to CHAI* – what needs to be done about dolutegravir pricing?

Pharmacokinetics of etravirine with once-daily and twice-daily dosing

Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects

Dolutegravir update: treatment-naive and -experienced patients and drug resistance

Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013

Non-standard combinations: NRTI-sparing combinations

High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+

Decreased growth in ART exposed uninfected infants in Botswana

Antiretrovirals, doses and formulations for children

Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro

Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance

S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir

Dolutegravir approved in the US

Community request Gilead to study and develop separate formulation of new tenofovir prodrug

ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc

ARV pipeline: long-acting formulations of rilpivirine, GSK-744 and nanoformulations

Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial

Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children

Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years

Pharmacokinetics of currently available antiretroviral options for young children

Safety of transplacental raltegravir in neonates and washout pharmacokinetics

Tenofovir use in children

ddI resistance in South African children failing an abacavir or d4T based first-line regimen

Study indicates rifampicin dose should be higher

Counter-intuitive result of IPT plus ART trial

START study increases sample size: additional 600 participants to be older than 35

WHO statement: generic antiretroviral therapy is safe and effective

Nevirapine-containing ART does not reduce combined oral contraceptive effectiveness

Differences by age for women in response to initial ART: meta-analysis from clinical studies submitted to the FDA

Lopinavir/ritonavir in pregnancy: results from a systematic review

Dolutegravir submitted to EU, US and Canadian regulatory agencies

Darunavir: new oral suspension and 800 mg formulations approved in EU

US label changes for rilpivirine and Eviplera follows EU caution on high baseline viral load: new summary on drug resistance

Post navigation